Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer Katelyn T. Byrne , Courtney B. Betts , Rosemarie Mick , Shamilene Sivagnanam , David L. Bajor , Daniel A. Laheru , E. Gabriela Chiorean , Mark H. O'Hara , Shannon M. Liudahl , Craig Newcomb , Cécile Alanio , Ana P. Ferreira , Byung S. Park , Takuya Ohtani , Austin P. Huffman , Sara A. Väyrynen , Andressa Dias Costa , Judith C. Kaiser , Andreanne M. Lacroix , Colleen Redlinger , Martin Stern , Jonathan A. Nowak , E. John Wherry , Martin A. Cheever , Brian M. Wolpin , Emma E. Furth , Elizabeth M. Jaffee , Lisa M. Coussens , Robert H. Vonderheide openalex（2024）
Key words
Neoadjuvant Therapy, Tumor Microenvironment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
